Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × bisantrene × Clear all

Phase

Status

Withdrawn 1 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cisplatin 474 Radiotherapy 345 Carboplatin 328 Cyclophosphamide 327 Capecitabine 308 Paclitaxel 307 Oxaliplatin 298 Docetaxel 285 Gemcitabine 283 Fluorouracil 258 apatinib 231 Drug Therapy 230 Bevacizumab 224 camrelizumab 194 Etoposide 179 Irinotecan 168 Doxorubicin 162 Dexamethasone 141 Leucovorin 137 Blood Specimen Collection 133 Cytarabine 131 pembrolizumab 127 Neoadjuvant Therapy 126 sintilimab 121 Pemetrexed 121 anlotinib 120 toripalimab 116 Rituximab 114 Surgical Procedures, Operative 113 S 1 (combination) 113

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04989335 2023-11-28

Bisantrene Combination for Resistant AML

Sheba Medical Center

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡